Cargando…

Cardiomyopathy and Response to Enzyme Replacement Therapy in a Male Mouse Model for Fabry Disease

Fabry disease is an X-linked disorder of glycosphingolipid metabolism that results in progressive accumulation of neutral glycosphingolipids, (predominately globotriaosylceramide; GL-3) in lysosomes, as well as other cellular compartments and the extracellular space. Our aim was to characterize the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nguyen Dinh Cat, Aurelie, Escoubet, Brigitte, Agrapart, Vincent, Griol-Charhbili, Violaine, Schoeb, Trenton, Feng, Wenguang, Jaimes, Edgar, Warnock, David G., Jaisser, Frederic
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3344819/ https://www.ncbi.nlm.nih.gov/pubmed/22574107 http://dx.doi.org/10.1371/journal.pone.0033743

Ejemplares similares

The Epidermal Growth Factor Receptor Is Involved in Angiotensin II But Not Aldosterone/Salt-Induced Cardiac Remodelling
por: Messaoudi, Smail, et al.
Publicado: (2012)

Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease
por: Fervenza, Fernando C, et al.
Publicado: (2008)

Impact of enzyme replacement therapy and migalastat on left atrial strain and cardiomyopathy in patients with Fabry disease
por: Pogoda, Christian, et al.
Publicado: (2023)

Adipocyte-Mineralocorticoid Receptor Alters Mitochondrial Quality Control Leading to Mitochondrial Dysfunction and Senescence of Visceral Adipose Tissue
por: Lefranc, Clara, et al.
Publicado: (2021)

Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy
por: Schiffmann, Raphael, et al.
Publicado: (2009)

Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease
por: Germain, Dominique P, et al.
Publicado: (2015)

Fabry Cardiomyopathy
por: Yoon, Jae Yong, et al.
Publicado: (2013)

Fabry nephropathy: 5 years of enzyme replacement therapy—a short review
por: Barbey, Frédéric, et al.
Publicado: (2008)

Fabry disease in children and the effects of enzyme replacement treatment
por: Pintos-Morell, Guillem, et al.
Publicado: (2009)

Cost-effectiveness of enzyme replacement therapy for Fabry disease
por: Rombach, Saskia M, et al.
Publicado: (2013)

Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease
por: Moore, David F, et al.
Publicado: (2002)

Long-Term Effect of Enzyme Replacement Therapy with Fabry Disease
por: Komori, Manabu, et al.
Publicado: (2013)

A Distinct Urinary Biomarker Pattern Characteristic of Female Fabry Patients That Mirrors Response to Enzyme Replacement Therapy
por: Kistler, Andreas D., et al.
Publicado: (2011)

Cardiac abnormalities in Anderson-Fabry disease and Fabry’s cardiomyopathy
por: Morrissey, Ryan P, et al.
Publicado: (2011)

Rapid Immunochromatographic Detection of Serum Anti-α-Galactosidase A Antibodies in Fabry Patients after Enzyme Replacement Therapy
por: Nakano, Sachie, et al.
Publicado: (2015)

Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document
por: Biegstraaten, Marieke, et al.
Publicado: (2015)

Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis
por: Beck, Michael, et al.
Publicado: (2015)

Gender Differences in the Application of Spanish Criteria for Initiation of Enzyme Replacement Therapy for Fabry Disease in the Fabry Outcome Survey
por: Barba-Romero, Miguel-Ángel, et al.
Publicado: (2016)

Fabry nephropathy before and after enzyme replacement therapy: important role of renal biopsy in patients with Fabry disease
por: Kim, Il Young, et al.
Publicado: (2021)

Enzyme replacement therapy for Fabry disease: some answers but more questions
por: Alfadhel, Majid, et al.
Publicado: (2011)

Enzyme replacement therapy and white matter hyperintensity progression in Fabry disease
por: Stefaniak, James D., et al.
Publicado: (2018)

Development of Lanzyme as the Potential Enzyme Replacement Therapy Drug for Fabry Disease
por: Deng, Mulan, et al.
Publicado: (2022)

Clinical features and enzyme replacement therapy in 10 children with Fabry disease
por: Li, Qian, et al.
Publicado: (2023)

Left ventricular hypertrophy in Fabry disease: a practical approach to diagnosis
por: Yousef, Zaheer, et al.
Publicado: (2013)

A Case of Fabry Cardiomyopathy
por: Nah, Jong Chun, et al.
Publicado: (2009)

Short-Term Efficacy of Enzyme Replacement Therapy in Korean Patients with Fabry Disease
por: Choi, Jin-Ho, et al.
Publicado: (2008)

Enzyme replacement therapy for Fabry disease: A systematic review and meta-analysis
por: Alegra, Taciane, et al.
Publicado: (2012)

Fabry disease: characterisation of the plasma proteome pre- and post-enzyme replacement therapy
por: Heo, Sun Hee, et al.
Publicado: (2017)

Genetic variants associated with Fabry disease progression despite enzyme replacement therapy
por: Scionti, Francesca, et al.
Publicado: (2017)

Effectiveness of enzyme replacement therapy in Fabry disease: Long term experience in Argentina
por: Cabrera, Gustavo, et al.
Publicado: (2017)

Variable clinical features of patients with Fabry disease and outcome of enzyme replacement therapy
por: Dutra-Clarke, Marina, et al.
Publicado: (2020)

Enzyme Replacement Therapy for FABRY Disease: Possible Strategies to Improve Its Efficacy
por: Iacobucci, Ilaria, et al.
Publicado: (2023)

Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: Analysis of prognostic factors
por: Arends, Maarten, et al.
Publicado: (2017)

An open-label clinical trial of agalsidase alfa enzyme replacement therapy in children with Fabry disease who are naïve to enzyme replacement therapy
por: Goker-Alpan, Ozlem, et al.
Publicado: (2016)

Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain
por: Rombach, Saskia M, et al.
Publicado: (2013)

Evaluating enzyme replacement therapies for Anderson-Fabry disease: commentary on a recent report
por: Giugliani, Roberto, et al.
Publicado: (2018)

Aberrant DNA methylation of calcitonin receptor in Fabry patients treated with enzyme replacement therapy
por: Hübner, Anna, et al.
Publicado: (2015)

Anti-drug antibody formation in Japanese Fabry patients following enzyme replacement therapy
por: Tsukimura, Takahiro, et al.
Publicado: (2020)

Diurnal Variation of Urinary Fabry Disease Biomarkers during Enzyme Replacement Therapy Cycles
por: Boutin, Michel, et al.
Publicado: (2020)

Urinary Mulberry Cells as a Biomarker of the Efficacy of Enzyme Replacement Therapy for Fabry Disease
por: Aoyama, Yumi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vgah60lif8es52p249j7ti111n